Which subgroup has a benefit-risk profile large enough to justify anti-amyloid antibody treatment once ARIA, monitoring burden, and absolute cognitive effect are modeled together?

Evidence span

Which subgroup has a benefit-risk profile large enough to justify anti-amyloid antibody treatment once ARIA, monitoring burden, and absolute cognitive effect are modeled together?

Method & conditions

Evidence type

theoretical

Method

manual state transition

Conditions

Candidate gap for maintainer review; not a guaranteed experiment target.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required